2025 Skoda Karoq Sportline ED TSI S-A 1.5L Petrol · EO25 UBM

No MOT history is currently recorded against this 2025 SKODA KAROQ SPORTLINE ED TSI S-A, which means no DVSA roadworthiness test outcome exists in the supplied data set. Given that the vehicle is a 2025 model and today's date is August 2026, the absence of any recorded test is entirely consistent with the car falling outside the statutory MOT testing window, which begins three years after first registration. There are therefore no pass, fail, or advisory entries to interpret, and no maintenance trend can be established from the official record. Mileage context is similarly absent. The DVSA MOT history does not include any odometer readings, and as no test has yet taken place there is no baseline figure against which future annual accumulation can be judged. Any assessment of whether the vehicle has covered high or low mileage for its one-year age cannot be made from this record alone, and mileage verification will need to be obtained from alternative documentation such as the V5C logbook, service invoices, or the in-person dashboard reading at the point of sale. In the absence of historical advisories or failure points, a prospective buyer cannot rely on the MOT file to shortlist components for inspection. Instead, the inspection focus must shift to the areas most likely to affect a low-mileage, nearly new SUV of this type: brake disc and pad condition given possible standing corrosion from short journeys, tyre age and tread depth including any uneven shoulder wear pointing to tracking or suspension geometry issues, the condition of the DSG automatic transmission fluid and mechatronic behaviour, and the underside for any early signs of corrosion or undertray damage. The paintwork, body panel alignment, and all driver-assistance sensors should also be physically verified, as these items are not covered by an MOT that has not yet been conducted. Records alone offer no reassurance here, and any positive statements about the vehicle's mechanical state or previous care would not be grounded in the supplied evidence. Buying_score: 50. Risk_level: Medium.